Navigation Links
PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
Date:6/13/2013

SAN FRANCISCO and NES-ZIONA, Israel, June 13, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.PROLOR's scientists will present additional pre-clinical and clinical safety data on hGH-CTP and will discuss its manufacturing process.  Data previously reported by the company confirmed that hGH-CTP appears to be safe and well tolerated and that it has the potential to be administered once-weekly to adults with growth hormone deficiency.  The new data provides further information on the excellent safety and tolerability profile of hGH-CTP in a variety of pre-clinical and clinical studies.  PROLOR recently announced that it has initiated a pivotal Phase III study of hGH-CTP in growth hormone deficient adults.

In addition, PROLOR scientists will make an oral presentation discussing MOD-6030, also known as LA-Oxyntomodulin, the company's long-acting GLP-1 and Glucagon dual agonist with potential for the treatment of type 2 diabetes and obesity.  New pre-clinical data will be presented on MOD-6030's effects on weight reduction and glucose tolerance in animal models.

The PROLOR presentations include the following:

FP02-3:  The Long-Acting Dual GLP-1/Glucagon Agonist, Mod-6030, Improves Glycemic Control and Induces a Prolonged Weight Loss in Diet-Induced Obesity Mice Following a Once-Weekly Administration.  See abstract for more information.

SAT-120:  Metabolic and Safety Parameters of Once-Weekly, CTP-
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
2. Law Office of Brodsky & Smith, LLC Announces Investigation of PROLOR Biotech, Inc.
3. OPKO Health To Acquire PROLOR Biotech
4. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
5. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
6. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
7. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
8. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. MedReps.com Report Shows Biotech Workers Earn the Most in Medical Sales
11. Biotechnology Master’s at UMBC Shady Grove - Virtual Info Session to Be Held on June 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MD (PRWEB) January 23, 2015 Portal ... modern digital workplaces on Microsoft Office 365 and SharePoint ... Future 50 Award program for being one of the region’s ... revenue and employee growth. , “To be recognized a ...
(Date:1/22/2015)... 2015  Transwestern | RBJ today announces the firm brokered a ... Shire a leading biopharmaceutical company, at Two Ledgemont Center in ... Robert Richards , president, and Brian Cohen , senior ... five-floor building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions driven ... record-breaking year across the board for the company. , ... and our Smart Data solutions, our customers were able to ... to record growth for the company in 2014,” said Alok ...
(Date:1/22/2015)... Rootstown, OH (PRWEB) January 22, 2015 Crystal ... announced today that it has received AOAC-PTM Certifications for the ... O111, O121, and O145; collectively referred to as STEC or ... at 1 colony forming unit (cfu) per 325 g of ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
... , ( NYSE Alternext US: CVM ... ended September 30, 2008.CEL-SCI reported a net loss for fiscal year ... year 2007. The loss per share per common share for ... common share in fiscal year 2007 of $(0.10). Included in the ...
... the Boston Atrial,Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: ... magnetic ablation that it believes will enhance the,efficiency, ... In booth #917, Stereotaxis will exhibit its ... System for enhanced remote,catheter control and improved EP ...
... meetings held in association,with the JP Morgan Healthcare Conference ... CTIC) reviewed 2009 targeted milestones and 2008,accomplishments. CTI is ... in,addition to potential label expansion for Zevalin(R). In November ... for Zevalin. , "With a ...
Cached Biology Technology:CEL-SCI Corporation Announces 2008 Financial Results 2CEL-SCI Corporation Announces 2008 Financial Results 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced today its ... confirm its adherence to current U.S. Food and Drug ... regulated smart device and smart phone application trials utilizing ... "HITLAB is determined to improve global healthcare ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... commercially available mineral waters, the researchers found evidence of ... the water. What,s more, these chemicals are potent in ... in the New Zealand mud snail. These findings, which ... of plastic food packaging materials act as functional estrogens, ...
... diseases that can travel with the wind have the ... understood, according to a new study, in findings that ... but also a new fungus that threatens global wheat ... State University and other institutions, concluded that invading diseases ...
... is available in Spanish . , ... of psychosis and schizophrenia, and those episodes of psychosis ... characteristics, both before their appearance and in the clinical ... conclusions of the doctoral thesis "Neurodevelopment and environmental stress ...
Cached Biology News:Hormone-mimics in plastic water bottles -- just the tip of the iceberg? 2New wheat disease could spread faster than expected 2New wheat disease could spread faster than expected 3Daily consumption of cannabis predisposes to the appearance of psychosis and schizophrenia 2
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood CD14+ monocytes, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Biology Products: